Focused on unmet clinical needs — a proprietary pipeline validated and continuously optimized.
Urinary tract infection (UTI) is the second most common infectious disease, affecting 150 million people worldwide annually. Most of the patients are women. CTG01 provides a new approach to preventing or even treating uropathogenic Escherichia coli infections by reducing bacterial adherence to host cells. Since CTG02 is not an antibiotic, there will be no issue of antibiotic resistance in the future.
Non-small cell lung cancer accounts for approximately 85% of all lung cancer cases, with around 2 million new cases diagnosed globally each year. China contributes 40% of these cases. CTG02 is a third-generation epidermal growth factor receptor inhibitor, and it can be developed as a small molecule targeted therapy for non-small cell lung cancer.Compared to Osimertinib, CTG02 has improved pharmacokinetic, therapeutic, and toxicological characteristics.
CTG03 is an IDO1 inhibitor. By inhibiting IDO1 in tumor cells and reducing indoleamine 2,3-dioxygenase (IDO), CTG03 can restore and promote the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer cells (NK cells), and T lymphocytes. This leads to tumor reduction.
CTG04 is an IDO1 inhibitor that can be used as a standalone therapy or in combination with other drugs. It can be developed as a novel class of medications for the treatment of various cancers, including non-small cell lung cancer, bladder cancer, melanoma, and more.
DX39105（Glucosylceramide Synthase Inhibitor）
As the first oral small-molecule candidate targeting lysosomal storage disorders (LSDs), DX39105 holds promise for treating multiple conditions driven by lysosomal metabolic dysfunction — including rare diseases such as Fabry disease and Gaucher disease — affecting over 100,000 patients worldwide.
Preclinical data have demonstrated its ability to significantly reduce pathogenic lipid accumulation, positioning DX39105 as the first Asia-originated therapy for lysosomal storage disorders.
Leveraging the AcuMed Innovations™ R&D platform, DX39105 has shown three breakthrough preclinical advantages:
DX39106（Next-Generation Musculoskeletal Analgesic & CNS Therapeutic Candidate）
DX39106 is a muscle relaxant that provides safe, low-toxicity pain management without the risk of addiction. It holds promise as a superior option for pain associated with degenerative and other musculoskeletal conditions in the elderly.
The candidate has completed comprehensive preclinical studies, demonstrating outstanding characteristics:
CTG07 is an HCN channel blocker that can be used to reduce the risk of hospitalization for worsening heart failure in adult patients and to treat stable symptomatic heart failure caused by dilated cardiomyopathy in pediatric patients.
CTG08 is a selective serotonin receptor agonist for 1b and 1d subtypes, which can be developed as a new chemical entity for the treatment of migraine. Migraine is typically accompanied by nausea, vomiting, and extreme sensitivity to light and sound, and can cause severe throbbing or pulsing pain.
CTG09, a Janus kinase (JAK) inhibitor, acts on the immune system and can be used to treat moderate to severe active rheumatoid arthritis, ulcerative colitis, and other related diseases.
CTG10 is an inhibitor of isocitrate dehydrogenase 1 (IDH1). IDH1 functions by reducing the abnormal production of the oncogenic metabolite 2-hydroxyglutarate, leading to malignant cell differentiation.
CTG11 is a farnesoid X receptor (FXR) agonist. FXR inhibits cholesterol synthesis, reduces the concentration of bile acids in liver cells, and promotes bile secretion, thereby reducing the exposure of the liver to bile acids.
CTG12 inhibits the growth of both androgen-dependent and androgen-independent prostate cancer cells. CTG12 can be developed as a potential novel drug for treating hormone-sensitive and hormone-refractory prostate cancer with minimal side effects.
CTG13 is a technology that applies cytokines for the early detection of tumors. After simple processing, human serum can be directly used in enzyme-linked immunosorbent assay (ELISA) to determine the presence of tumor cells in the human body through colorimetric and fluorescence detection.
CTG14 is a phosphoinositide 3-kinase (PI3K) inhibitor that blocks the P110δ, the subtype of PI3K. It can be developed to treat relapsed chronic lymphocytic leukemia (CLL).
CTG15 reduces fibroblast proliferation, inhibits collagen production stimulated by transforming growth factor β, and decreases the production of fibrogenic mediators. AI calculations indicate that CTG15 may be utilized in the treatment of idiopathic pulmonary fibrosis.
CTG16 is a synthetic flavonoid compound with the ability to penetrate the brain and activate receptors (TrkB) that facilitate neuronal growth. Experimental findings indicate that CTG16 may possess certain cognitive and motor advantages. Thus, CTG16 can be developed as a potential nootropic agent.
